This collaboration will inform how small-to-medium sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved. The agreement with Osmind further expands the set of collaborations that Compass has established to inform the potential delivery of COMP360 in a broad spectrum of settings where people living with mental health conditions receive their care in the United States. 

 

Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind's network of over 1,000 clinics comprises one of the country's largest network of interventional psychiatry practices. Its psychiatry-tailored software and services are designed to enable clinicians to offer innovative psychiatric treatments sustainably, without giving up independence. Together, Compass and Osmind aim to better understand the operational, clinical, and infrastructure needs of independent psychiatry practices, and to help inform scalable, real-world pathways for the potential delivery of psychedelic treatments in community-based settings.